



ASSERT-IQ™
INSERTABLE CARDIAC MONITOR (ICM)



DESIGNED TO OUTPERFORM, **BUILT TO OUTLAST**

Longest Lasting Bluetooth® ICM†
Advanced Algorithms
New IQ Insights
Remote Programmability

DESIGNED TO **OUTPERFORM**


Having pioneered the introduction of the world's first Bluetooth®-enabled insertable cardiac monitor (ICM), Abbott is leading innovation once more with the introduction of Assert-IQ™ ICM. With Assert-IQ ICM, you will be able to detect arrhythmias more accurately¹⁻³, see EGM details more clearly*, and gain additional insights to enable more informed decision making⁴, all powered by state-of-the-art Bluetooth® technology and remote programming capabilities**. We have created an ICM that provides meaningful value in the areas that are most important to you and your clinic.

BUILT TO **OUTLAST**

It's imperative that technology keeps pace with the changing needs of patients who benefit from remote monitoring with an ICM. That's why we are offering two battery life options: minimum of 3 years, which may be preferred for more traditional reasons for monitoring, such as diagnosing syncope, palpitations, or detection of AF within cryptogenic stroke patients; or minimum of 6 years, which may be preferred for monitoring patients more longer term, such as those who are undergoing therapy and are at risk of developing further arrhythmias.




ASSERT-IQ 3+ | 3+ YEAR^{***}: MAY BE PREFERRED FOR TRADITIONAL CARDIAC MONITORING.



ASSERT-IQ EL+ | 6+ YEAR^{***}: LONGER TERM MONITORING; MAY BE PREFERRED FOR AF MANAGEMENT. <10% longer, 3+ more years battery than the Assert-IQ 3+

* Compared to predicate devices
 ** Available on DM5300/DM5500
 *** Data on File. Abbott - Report 90984075.

LONGEST LASTING **BLUETOOTH® ICM**, WITH FULL FUNCTIONALITY AND NO COMPROMISES⁴⁻⁹ TO SUPPORT THE EXPANDING PATIENT MANAGEMENT NEEDS OF YOUR PRACTICE.



* Model DM5500

ADVANCED ALGORITHMS THAT PROVIDE CLINICALLY ACTIONABLE DATA

Our highly effective discriminators assist in reducing your clinic's data burden all without compromising the device's ability to detect true events. Our advanced algorithms reduce false detections by 98.7% for AF and Pause, while maintaining 97.7% of true EGMs.^{1,2,10}


When compared to the latest version of LINQ II[‡], Assert-IQ ICM's AF algorithm reduces data burden by 21% while maintaining sensitivity.^{*,1,11,12}

PERFORMANCE BY THE NUMBERS

ASSERT-IQ ICM'S AF ALGORITHM REDUCES DATA BURDEN BY

21%

COMPARED TO THE LATEST VERSION OF LINQ II[‡] ^{*,1,11,12}



ADVANCED ALGORITHMS
FALSE DETECTION REDUCTION FOR AF AND PAUSE^{1,2,10}

5 Assert-IQ ICM utilizes a **5-step AF detection discriminator** that focuses on R-R interval patterns and P-waves in EGMs to verify if an event is true or false.


KEY EPISODES[^] – OPTIMIZED FOR EACH ARRHYTHMIA TYPE

Key Episode Technology sets Assert-IQ ICM apart from others that use a standard set of criteria for all types of arrhythmias. The cloud-based feature not only evaluates each arrhythmia differently, ensuring more clinically useful data is reported, but this feature can be toggled on/off according to the needs of your patients and clinic, allowing you the flexibility to see all episodes or 3 Key Episodes.[^]

Arrhythmia Type	Assert-IQ [™] ICM Key Episode Selection: Up to 3 EGMs per day, per arrhythmia type ⁴	Medtronic Reveal LINQ [‡] Selection: One EGM per day based on wireless data priority ⁵	Medtronic LINQ II [‡] Selection: Three auto episode EGMs per day per arrhythmia type ⁶
Atrial Fibrillation	1. Longest episode 2. Second longest episode 3. Fastest mean rate	One EGM per day sent wirelessly	Same standard criteria set for all arrhythmia types
Tachycardia	1. Longest episode 2. Second longest episode 3. Fastest maximum rate		
Bradycardia	1. Longest episode 2. Second longest episode 3. Fastest minimum rate	Patient manual transmission optional to see all information ³	1. First episode 2. Second episode 3. Longest episode
Pause	1. Longest episode 2. Second longest episode 3. Shortest episode		

CLEAR, CRISP EGMs

Get clear, crisp EGMs for improved visualization of P-waves, which could lead to a faster care decision for your patients.¹³



[^] Key Episodes is a feature of Merlin.net[™] PCN.

^{*}As of 12.31.22, LINQ II[‡] with AccuRhythm[®] AI. EGM burden comparison is based on two independent, random, real-world data sets. Patient characteristics and device programming may differ.

NEW IQ INSIGHTS

With IQ Insights, clinicians can make data-driven decisions faster and more confidently. Additional sensors on the Assert-IQ™ ICM capture these exciting new diagnostics:



PREMATURE VENTRICULAR CONTRACTIONS (PVCs)

Leading PVC detection algorithm that offers the ability to capture consecutive events including couplets and triplets.¹⁴



BODY POSITION & POSTURE CHANGES

at episode onset enables you to assess other patient factors to help adjudicate episodes.



The only ICM that tracks **ELEVATED HEART RATE WITH AND WITHOUT ACTIVITY.**⁴⁻⁹




DIRECT TREND VIEWER

allows you to assess AF, PVCs, and activity trends. Available on Merlin.net™ PCN for the lifetime of the device.

AND MORE.

REMOTE PROGRAMMING TO ENHANCE YOUR CLINIC'S WORKFLOW

Remote programming allows you to adjust the settings of the device, optimize performance, and limit unnecessary alerts or transmissions for connected devices - all without requiring the patient to visit the clinic.*



A LEADER IN BLUETOOTH® ICM TECHNOLOGY

Advanced Bluetooth® technology checks in every 20 seconds with the connected device (this is also known as the advertising rate), to capture, encrypt, and transfer data to the Merlin.net Patient Care Network (PCN) quickly and easily.



CHECKS IN EVERY **20 SECONDS** AUTOMATICALLY, WITHOUT ANY ACTION NEEDED BY THE PATIENT.



DATA CAPTURE, ENCRYPTION, AND TRANSFER TO MERLIN.NET PCN THROUGH myMERLIN MOBILE APP

RELIABLE SUPPORT FOR REMOTE MONITORING

HELPING YOUR PATIENTS GET CONNECTED AND STAY CONNECTED

Abbott's SyncUP™ Remote Monitoring Support experts work directly with patients of enrolled clinics to set up their myMerlin™ Mobile App so that it is connected with their ICM and can send data to their clinic. SyncUP Remote Monitoring Support contacts enrolled patients to provide one-on-one education to help a patient understand how to use the app and how remote monitoring works - all from the comfort of their home. Clinics enrolled in the program receive a weekly report on remote patient monitoring compliance, which helps streamline workflow.



Assert-IQ™ ICM

PATIENT SMARTPHONE*

CLINICIAN PORTAL

*Patients can use an Abbott-provided mobile transmitter if they do not have a compatible smartphone.

Assert-IQ™ ICM. Only from Abbott.

Powered by SyncUP Remote Monitoring Support and myMerlin Mobile App, Assert-IQ ICM provides the flexibility to deliver data the way you and your patients need.

REFERENCES:

- Gopinathannair R, Lakkireddy D, Manyam H, et al. Improving the Specificity of Atrial Fibrillation and Tachycardia Detection in an Insertable Cardiac Monitor. Presented at Heart Rhythm Society (HRS); San Francisco, USA; 2022.
- Afzal MR, Gopinathannair R, Manyam H, et al. Development and Evaluation of a New Algorithm Enhancement to Improve Specificity of Pause Detection in an Insertable Cardiac Monitor. Presented at Heart Rhythm Society (HRS); San Francisco, USA; 2022.
- Gardner RS, Quartieri F, Betts TR, et al. Reducing the Electrogram Review Burden Imposed by Insertable Cardiac Monitors. J Cardiovascular Electrophysiology. 2022;33(4):741-750. doi:10.1111/jce.15397
- Abbott. Assert-IQ ICM User Manual.
- Medtronic. REVEAL LINQ⁺ LNQ11 Insertable Cardiac Monitor and Patient Assistant PA96000 Clinician Manual. Updated August 26, 2015. Accessed January 17, 2023. https://manuals.medtronic.com/content/dam/emanuals/crdm/CONTRIB_215651.pdf
- Medtronic. LINQ II⁺ LNQ22 Insertable Cardiac Monitor Clinician Manual. Updated September 01, 2022. Accessed January 17, 2023. https://manuals.medtronic.com/content/dam/emanuals/crdm/M032283C001B_view.pdf
- Boston Scientific. User's Manual, Lux-Dx⁺ Insertable Cardiac Monitor System M301, 2925, 2935. Updated July 2020. Accessed January 17, 2023. https://www.bostonscientific.com/content/dam/Manuals/us/current-rev-en/92216689-002_LUX-Dx_UM_en_S.pdf
- Biotronik. Technical Manual BioMonitor III⁺. Updated December 10, 2020. Accessed January 17, 2023. https://manuals.biotronik.com/emanuals-professionals/?country=US&product=ImplCardMon/BioMonitor3/BioMonitor3_US
- Biotronik. Technical Manual BioMonitor III^m. Updated December 10, 2020. Accessed January 17, 2023. https://manuals.biotronik.com/emanuals-professionals/?country=US&product=ImplCardMon/BioMonitor3m/BioMonitor3m_US
- Data on File. Abbott - Report SJM-CFM-0919-0163.
- Radtke, et al. Artificial Intelligence Enables Dramatic Reduction of False Atrial Fibrillation Alerts from Insertable Cardiac Monitors. Presented at Heart Rhythm Society (HRS); Boston, USA; Aug 2021.
- Data on File. Abbott - Report 90986479A; AF EGM Burden Reduction in Assert-IQ ICM.
- Shehata MM, Nair DG, Qu F, et al. Insertable Cardiac Monitor P-wave Visibility in a New Clinical Report. Presented at Asia Pacific Heart Rhythm Society (APHRS); Bangkok Thailand; 2022.
- Manyam H, Afzal MR, Gopinathannair R, et al. Evaluation of A Novel Premature Ventricular Contraction Detection Algorithm in an Insertable Cardiac Monitor. Presented at Heart Rhythm Society (HRS); San Francisco, USA; 2022.

† As of 12.31.22. Reveal LINQ⁺ User Manual, LINQ II⁺ User Manual, Lux Dx⁺ User Manual, Biomonitor III⁺ User Manual, Biomonitor III^m User Manual.



Contact your Abbott Sales Representative or visit cardiovascular.abbott/AssertIQ



Assert-IQ™ ICM

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications for Use: The Assert-IQ™ ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms that may be cardiac-related such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias such as bradycardia, tachycardia, and sinus pauses.

The Assert-IQ ICM is also indicated for patients who have been previously diagnosed with atrial fibrillation (AF) or who are susceptible to developing AF. The Assert-IQ ICM is intended to be inserted subcutaneously in the left pectoral region, also described as the left anterior chest wall. The Assert-IQ ICM has not been specifically tested for pediatric use.

Intended Use: The Assert-IQ ICM is intended to help physicians and clinicians monitor, diagnose and document the heart rhythm in patients who are susceptible to cardiac arrhythmias and unexplained symptoms by detecting arrhythmias and transmitting data for review.

Contraindications: There are no known contraindications for the insertion of the Assert-IQ ICM. However, the patient's particular medical condition may dictate whether or not a subcutaneous, chronically inserted device can be tolerated.

Potential Adverse Events: Possible adverse events (in alphabetical order) associated with the device, include the following: allergic reaction, bleeding, chronic nerve damage, erosion, excessive fibrotic tissue growth, extrusion, formation of hematomas or cysts, infection, keloid formation and migration.

Refer to the User's Manual for detailed indications for use, contraindications, warnings, precautions and potential adverse events.

An Abbott mobile transmitter is available for patients without their own compatible mobile device.

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third-party trademark, which is property of its respective owner. Bluetooth and Bluetooth logo are registered trademarks of Bluetooth SIG, Inc.

Abbott

15900 Valley View Court, Sylmar, CA 91342

Tel: +1 818 362 6822

[Abbott.com](https://www.abbott.com)

© 2023 Abbott. All Rights Reserved.

MAT-2301251 v4.0 | Item approved for U.S. use.

